664 related articles for article (PubMed ID: 33216643)
1. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
[No Abstract] [Full Text] [Related]
2. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
Ciechanowicz P; Dopytalska K; Mikucka-Wituszyńska A; Dźwigała M; Wiszniewski K; Herniczek W; Szymańska E; Walecka I
J Dermatolog Treat; 2022 May; 33(3):1581-1584. PubMed ID: 33317364
[TBL] [Abstract][Full Text] [Related]
3. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M; Tofani L; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2020 Aug; 20(8):829-830. PubMed ID: 32510244
[TBL] [Abstract][Full Text] [Related]
4. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.
Gisondi P; Piaserico S; Naldi L; Dapavo P; Conti A; Malagoli P; Marzano AV; Bardazzi F; Gasperini M; Cazzaniga S; Costanzo A;
J Allergy Clin Immunol; 2021 Feb; 147(2):558-560.e1. PubMed ID: 33160968
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and psoriasis: biologic treatment and challenges.
Ebrahimi A; Sayad B; Rahimi Z
J Dermatolog Treat; 2022 Mar; 33(2):699-703. PubMed ID: 32598204
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
Polat Ekinci A; Pehlivan G; Gökalp MO
Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
[TBL] [Abstract][Full Text] [Related]
7. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
8. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.
Gisondi P; Geat D; Bellinato F; Girolomoni G
Expert Opin Biol Ther; 2022 Dec; 22(12):1521-1529. PubMed ID: 35930356
[TBL] [Abstract][Full Text] [Related]
9. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
[TBL] [Abstract][Full Text] [Related]
10. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone.
Brazzelli V; Isoletta E; Barak O; Barruscotti S; Vassallo C; Giorgini C; Michelerio A; Tomasini CF; Musella V; Klersy C
Dermatol Ther; 2020 Nov; 33(6):e14516. PubMed ID: 33169500
[TBL] [Abstract][Full Text] [Related]
11. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
Ladda M; Lynde C; Fleming P
J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
[TBL] [Abstract][Full Text] [Related]
12. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
Damiani G; Pacifico A; Bragazzi NL; Malagoli P
Dermatol Ther; 2020 Sep; 33(5):e13475. PubMed ID: 32356577
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.
Ghoreishi Amin N; Khosravi S; Atefi N; Seirafianpour F; Farhoodi S; Goodarzi A
Immun Inflamm Dis; 2023 Nov; 11(11):e1063. PubMed ID: 38018599
[TBL] [Abstract][Full Text] [Related]
14. Biologic drugs during COVID-19 outbreak.
Montesu MA; Biondi G; Sotgiu G; Sucato F; Satta R
Int J Dermatol; 2020 Oct; 59(10):1293. PubMed ID: 32767379
[No Abstract] [Full Text] [Related]
15. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
[TBL] [Abstract][Full Text] [Related]
16. Impact of the COVID-19 pandemic on biologic treatment in psoriasis patients: A single-center retrospective study in Japan.
Uchida H; Kamata M; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol; 2022 Jun; 49(6):624-628. PubMed ID: 35319126
[TBL] [Abstract][Full Text] [Related]
17. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
[TBL] [Abstract][Full Text] [Related]
18. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy.
Piaserico S; Gisondi P; Cazzaniga S; Naldi L
Am J Clin Dermatol; 2020 Oct; 21(5):749-751. PubMed ID: 32812188
[No Abstract] [Full Text] [Related]
19. How lockdown measures, during COVID-19 pandemic, matter on psoriatic patient's perception: Study on 600 patients on biologic therapy.
Bernardini N; Skroza N; Spagnoli A; Marchesiello A; Balduzzi V; Tolino E; Mambrin A; Michelini S; Maddalena P; Volpe S; Proietti I; Vestri A; Potenza C
J Infect Public Health; 2021 Jul; 14(7):878-882. PubMed ID: 34118738
[TBL] [Abstract][Full Text] [Related]
20. Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.
Mroz M; Mućka S; Miodońska M; Ziolkowska D; Hadas E; Bożek A
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
